Search

Your search keyword '"Labianca R."' showing total 1,072 results
Start Over Author "Labianca R."
1,072 results on '"Labianca R."'

54. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007

Author

Van Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J.-F, Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Glynne-Jones, R., Haller, D., Kang, Y.-K., Kerr, D., Labianca, R., Minsky, B. D., Moore, M., Nordlinger, B., Rougier, P., Scheithauer, W., Schmoll, H.-J., Sobrero, A., Tabernero, J., Tempero, M., Van de Velde, C., and Zalcberg, J.

Published
2008

56. Consensus and controversies regarding follow-up after treatment with curative intent of nonmetastatic colorectal cancer: a synopsis of guidelines used in countries represented in the European Society of Coloproctology

Author

Bastiaenen, V.P., Hovdenak Jakobsen, I., Labianca, R., Martling, A., Morton, D.G., Primrose, J.N., Tanis, P.J., and Laurberg, S.

Abstract

AIM: It is common clinical practice to follow patients for a period of years after treatment with curative intent of nonmetastatic colorectal cancer, but follow-up strategies vary widely. The aim of this systematic review was to provide an overview of recommendations on this topic in guidelines from member countries of the European Society of Coloproctology, with supporting evidence.METHOD: A systematic search of Medline, Embase and the guideline databases Trip database, BMJ Best Practice and Guidelines International Network was performed. Quality assessment included use of the AGREE-II tool. All topics with recommendations from included guidelines were identified and categorized. For each subtopic, a conclusion was made followed by the degree of consensus and the highest level of evidence.RESULTS: Twenty-one guidelines were included. The majority recommended that structured follow-up should be offered, except for patients in whom treatment of recurrence would be inappropriate. It was generally agreed that clinical visits, measurement of carcinoembryoinc antigen and liver imaging should be part of follow-up, based on a high level of evidence, although the frequency is controversial. There was also consensus on imaging of the chest and pelvis in rectal cancer, as well as endoscopy, based on lower levels of evidence and with a level of intensity that was contradictory.CONCLUSION: In available guidelines, multimodal follow-up after treatment with curative intent of colorectal cancer is widely recommended, but the exact content and intensity are highly controversial. International agreement on the optimal follow-up schedule is unlikely to be achieved on current evidence, and further research should refocus on individualized 'patient-driven' follow-up and new biomarkers.

Published
2019

60. The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006

Author

Verslype, C., Van Cutsem, E., Dicato, M., Cascinu, S., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Haller, D., Haustermans, K., Heinemann, V., Hoff, P., Johnston, P. G., Kerr, D., Labianca, R., Louvet, C., Minsky, B., Moore, M., Nordlinger, B., Pedrazzoli, S., Roth, A., Rothenberg, M., Rougier, P., Schmoll, H.-J., Tabernero, J., Tempero, M., van de Velde, C., Van Laethem, J.-L., and Zalcberg, J.

Published
2007

65. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005

Author

Van Cutsem, E., Dicato, M., Arber, N., Benson, A., Cunningham, D., Diaz-Rubio, E., Glimelius, B., Goldberg, R., Haller, D., Haustermans, K., Koo-Kang, Y., Labianca, R., Lang, I., Minsky, B., Nordlinger, B., Roth, A., Rougier, P., Schmoll, H.-J., Sobrero, A., Tabernero, J., Szawlowski, A., and van de Velde, C.

Published
2006

67. Introduction

Author

Cartei, G. and Labianca, R.

Published
2006

74. Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

Author

Vernieri, C, Galli, F, Ferrari, L, Marchetti, P, Lonardi, S, Maiello, E, Iaffaioli, R, Zampino, M, Zaniboni, A, De Placido, S, Banzi, M, Damiani, A, Ferrari, D, Rosati, G, Labianca, R, Bidoli, P, Frassineti, G, Nicolini, M, Pavesi, L, Tronconi, M, Buonadonna, A, Ferrario, S, Re, G, Adamo, V, Tamburini, E, Clerico, M, Giordani, P, Leonardi, F, Barni, S, Ciarlo, A, Cavanna, L, Gori, S, Cinieri, S, Faedi, M, Aglietta, M, Antista, M, Dotti, K, Di Bartolomeo, M, Iaffaioli, RV, Zampino, MG, Labianca, RF, Frassineti, GL, Tronconi, MC, Re, GL, Dotti, KF, Vernieri, C, Galli, F, Ferrari, L, Marchetti, P, Lonardi, S, Maiello, E, Iaffaioli, R, Zampino, M, Zaniboni, A, De Placido, S, Banzi, M, Damiani, A, Ferrari, D, Rosati, G, Labianca, R, Bidoli, P, Frassineti, G, Nicolini, M, Pavesi, L, Tronconi, M, Buonadonna, A, Ferrario, S, Re, G, Adamo, V, Tamburini, E, Clerico, M, Giordani, P, Leonardi, F, Barni, S, Ciarlo, A, Cavanna, L, Gori, S, Cinieri, S, Faedi, M, Aglietta, M, Antista, M, Dotti, K, Di Bartolomeo, M, Iaffaioli, RV, Zampino, MG, Labianca, RF, Frassineti, GL, Tronconi, MC, Re, GL, and Dotti, KF

Abstract

Background: Type 2 diabetes mellitus (T2DM) is associated with increased risk of colon cancer (CC), whereas metformin use seems to be protective. However, the impact of metformin use on the risk of death or disease recurrence after radical surgery for CC remains uncertain. Materials and Methods: This is a substudy conducted in patients with high-risk stage II or stage III CC randomized in the TOSCA trial, which compared 3 versus 6 months of fluoropyrimidine-oxaliplatin adjuvant chemotherapy. Objective of the study was to investigate the impact of metformin exposure during adjuvant chemotherapy on overall survival (OS) and relapse-free survival (RFS). We also evaluated the impact of T2DM or metformin dosage on clinical outcomes. Results: Out of 3,759 patients enrolled in the TOSCA trial, 133 patients with diabetes (9.2%) and 1,319 without diabetes (90.8%) were recruited in this study. After excluding 13 patients with diabetes without information on metformin exposure, 76 patients with T2DM (63.3%) were defined as metformin users and 44 (36.7%) as metformin nonusers. After a median follow-up of 60.4 months, 26 (21.7%) patients relapsed and 16 (13.3%) died. Metformin use was neither associated with OS (adjusted hazard ratio [HR], 1.51; 95% confidence interval [CI], 0.48–4.77; p =.4781) nor with RFS (HR, 1.56; 95% CI, 0.69–3.54; p =.2881). Similarly, we found no association between T2DM or metformin dosage and OS or RFS. Conclusions: Metformin use and T2DM did not impact on OS or RFS in patients with resected CC treated with adjuvant fluoropyrimidine-oxaliplatin chemotherapy. Larger studies and longer follow-up are required to clarify the potential efficacy of metformin in improving the prognosis of patients with CC. Implications for Practice: The role of the antidiabetic drug metformin in colon cancer prevention and treatment is highly debated. While low-dose metformin reduced the incidence of colorectal adenomas in two prospective studies, its effect in patients with

Published
2019

75. Treatment of venous thromboembolism with tinzaparin in oncological patients

Author

Ageno, W, Barni, S, Di Nisio, M, Falanga, A, Imberti, D, Labianca, R, Mantovani, L, Ageno, Walter, Barni, Sandro, Di Nisio, Marcello, Falanga, Anna, Imberti, Davide, Labianca, Roberto F, Mantovani, Lorenzo, Ageno, W, Barni, S, Di Nisio, M, Falanga, A, Imberti, D, Labianca, R, Mantovani, L, Ageno, Walter, Barni, Sandro, Di Nisio, Marcello, Falanga, Anna, Imberti, Davide, Labianca, Roberto F, and Mantovani, Lorenzo

Abstract

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. For over a decade, the gold standard of treatment and secondary prevention of cancer-associated thrombosis (CAT) has been represented by low-molecular-weight heparins (LMWHs), which are currently recommended as the first-line treatment for CAT. Among the LMWHs that were more extensively tested in patients with CAT, tinzaparin is a LMWH produced by the enzymatic degradation of porcine-derived unfractionated heparin. The efficacy of tinzaparin in this setting is supported by well-grounded evidence. However, there is a need to discuss the positioning of tinzaparin in the continuously evolving treatment scenario of VTE therapy in cancer patients. In this paper, which was developed by a group of clinicians with wide experience in the treatment of VTE in cancer patients, we discuss the current therapeutic options and the role of tinzaparin for the treatment of CAT.

Published
2019

76. Insurance for independent cancer trials

Author

Perrone, F., Marangolo, M., Di Costanzo, F., Colucci, G., Repetto, L., Merlano, M., De Placido, S., Torri, V., Comella, G., Labianca, R., Parisi, V., and Gallo, C.

Published
2004

84. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)

Author

Cascinu, S., Graziano, F., Ferraù, F., Catalano, V., Massacesi, C., Santini, D., Silva, R. R., Barni, S., Zaniboni, A., Battelli, N., Siena, S., Giordani, P., Mari, D., Baldelli, A. M., Antognoli, S., Maisano, R., Priolo, D., Pessi, M. A., Tonini, G., Rota, S., and Labianca, R.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results